[go: up one dir, main page]

ES2008759A6 - Procedimiento para la fabricacion de un hidrato del acido 7b -(z)-2-(2-aminotiazol-4-il)-4-carboxibut-2-enoilamino -3- cefem-4-carboxilico. - Google Patents

Procedimiento para la fabricacion de un hidrato del acido 7b -(z)-2-(2-aminotiazol-4-il)-4-carboxibut-2-enoilamino -3- cefem-4-carboxilico.

Info

Publication number
ES2008759A6
ES2008759A6 ES8703123A ES8703123A ES2008759A6 ES 2008759 A6 ES2008759 A6 ES 2008759A6 ES 8703123 A ES8703123 A ES 8703123A ES 8703123 A ES8703123 A ES 8703123A ES 2008759 A6 ES2008759 A6 ES 2008759A6
Authority
ES
Spain
Prior art keywords
carboxibut
aminotiazol
cefem
procedure
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8703123A
Other languages
English (en)
Inventor
Yoshio Hamashima
Kyoji Minami
Kyozo Kawata
Teruo Sakamoto
Toyohiko Takeda
Yusuke Suzuki
Masanori Tujikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61156954A external-priority patent/JP2544113B2/ja
Priority claimed from JP21626086A external-priority patent/JPH0717651B2/ja
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of ES2008759A6 publication Critical patent/ES2008759A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCEDIMIENTO PARA LA FABRICACION DE UN HIDRATO DEL ACIDO 7þLY19BþLY01-[(Z)-2-(2-AMINOTIAZOL-4-IL)-4-CARBOXIBUT-2-ENOILAMINO]-3-CEFEM-4-CARBOXILICO. COMPRENDE EL SECADO DE CRISTALES HUMEDOS DEL MISMO, POR SECADO ESTACIONARIO, DE FLUJO PASANTE, POR CIRCULACION O POR LECHO FLUIDIFICADO EN UN GAS INERTE CON UNA HUMEDAD RELATIVA NO INFERIOR A 15% A UNA TEMPERATURA COMPRENDIDA ENTRE 0 Y 60GC.
ES8703123A 1986-07-02 1987-11-02 Procedimiento para la fabricacion de un hidrato del acido 7b -(z)-2-(2-aminotiazol-4-il)-4-carboxibut-2-enoilamino -3- cefem-4-carboxilico. Expired ES2008759A6 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61156954A JP2544113B2 (ja) 1986-07-02 1986-07-02 安定なカプセル製剤
JP21626086A JPH0717651B2 (ja) 1986-09-12 1986-09-12 経口投与用セフアロスポリン水和物結晶

Publications (1)

Publication Number Publication Date
ES2008759A6 true ES2008759A6 (es) 1989-08-01

Family

ID=26484565

Family Applications (2)

Application Number Title Priority Date Filing Date
ES8702189A Expired ES2004952A6 (es) 1986-07-02 1987-07-02 Perfeccionamientos en la fabricacion de capsulas para hidratos cristalinos de cefalosporina
ES8703123A Expired ES2008759A6 (es) 1986-07-02 1987-11-02 Procedimiento para la fabricacion de un hidrato del acido 7b -(z)-2-(2-aminotiazol-4-il)-4-carboxibut-2-enoilamino -3- cefem-4-carboxilico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES8702189A Expired ES2004952A6 (es) 1986-07-02 1987-07-02 Perfeccionamientos en la fabricacion de capsulas para hidratos cristalinos de cefalosporina

Country Status (27)

Country Link
US (2) US4812561A (es)
KR (1) KR950005302B1 (es)
CN (1) CN1015106B (es)
AR (1) AR243893A1 (es)
AT (1) AT392472B (es)
AU (1) AU594167B2 (es)
BE (1) BE1001691A4 (es)
CA (1) CA1283405C (es)
CH (1) CH672788A5 (es)
DE (1) DE3721913A1 (es)
DK (1) DK161080C (es)
ES (2) ES2004952A6 (es)
FI (1) FI89052C (es)
FR (1) FR2601014B1 (es)
GB (1) GB2192183B (es)
GR (1) GR871014B (es)
HK (1) HK47893A (es)
HU (1) HU200777B (es)
IE (1) IE59613B1 (es)
IL (1) IL83059A (es)
IT (1) IT1211469B (es)
NL (1) NL193136C (es)
NO (1) NO170889C (es)
NZ (1) NZ220764A (es)
PL (1) PL159180B1 (es)
RU (1) RU1829932C (es)
SE (1) SE466257B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
NZ252433A (en) * 1992-04-30 1996-07-26 Schering Corp Preparation of a dry hydrated cephalosporin powder formulation which is resistant to air oxidation and dehydration by mixing the drug with dry excipients and filling into a sealable storage container
ATE544789T1 (de) * 1998-10-27 2012-02-15 Westlake Longview Corp Verfahren zur olefinpolymerisation, neue polyethylene und daraus hergestellte folien und artikel
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
AT412213B (de) * 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) * 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
MX2009006877A (es) 2006-12-22 2009-09-28 Schering Corp Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
CN101611002A (zh) * 2006-12-22 2009-12-23 先灵公司 用于治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
AU2007339382B2 (en) 2006-12-22 2013-05-02 Merck Sharp & Dohme Llc 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
AU2008295484B2 (en) 2007-08-29 2013-09-26 Merck Sharp & Dohme Llc Substituted indole derivatives and methods of use thereof
AR068108A1 (es) * 2007-08-29 2009-11-04 Schering Corp Derivados azaindol 2,3-sustituidos y una composicion farmaceutica
CN101842353A (zh) * 2007-08-29 2010-09-22 先灵公司 用于治疗病毒感染的2,3-取代的吲哚衍生物
JP5416708B2 (ja) * 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
CA2727620A1 (en) * 2008-06-13 2009-12-17 Schering Corporation Tricyclic indole derivatives and methods of use thereof
TW201020238A (en) 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
TW201019939A (en) 2008-08-20 2010-06-01 Schering Corp Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
HRP20191005T1 (hr) 2009-07-06 2019-08-23 Boehringer Ingelheim International Gmbh Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
EP2566449B1 (en) 2010-05-04 2014-10-08 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9061041B2 (en) 2011-04-13 2015-06-23 Merck Sharp & Dohme Corp. 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2013151518A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Capsule formulations comprising ceftibuten
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103948932B (zh) * 2014-04-17 2016-03-16 海南日中天制药有限公司 一种头孢克肟组合物及其制备方法
EP3031450A1 (en) 2014-12-12 2016-06-15 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten capsule compositions
CA3022684A1 (en) 2016-05-13 2017-11-16 Aeromics, Inc. Crystals
JP7060245B2 (ja) 2016-06-30 2022-04-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
CN106397454B (zh) * 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
CN106432271A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432270A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432272A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106397457A (zh) * 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
US20240327426A1 (en) * 2021-07-01 2024-10-03 Qpex Biopharma, Inc. Crystalline forms of ceftibuten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819620A (en) * 1972-06-01 1974-06-25 Squibb & Sons Inc 7-(d-alpha-amino-1,4-cyclohexadien-1-ylacet-amido)desacetoxycephalosporanic acid dihydrate
JPS5726692A (en) * 1980-07-22 1982-02-12 Fujisawa Pharmaceut Co Ltd Preparation of stable crystal of salt of ceftizoxime
DE3037997A1 (de) * 1980-10-08 1982-05-13 Bayer Ag (beta) -lactamantibiotika, verfahren zu deren herstellung sowie sie enthaltende mittel
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters

Also Published As

Publication number Publication date
NO170889C (no) 1992-12-23
KR880001670A (ko) 1988-04-26
SE8702705D0 (sv) 1987-06-30
PL266567A1 (en) 1988-07-21
NO872729L (no) 1988-01-04
RU1829932C (ru) 1993-07-23
IT1211469B (it) 1989-11-03
GR871014B (en) 1987-11-02
IE871738L (en) 1988-01-02
CH672788A5 (es) 1989-12-29
GB2192183A (en) 1988-01-06
IL83059A0 (en) 1987-12-31
ES2004952A6 (es) 1989-02-16
IT8767566A0 (it) 1987-07-01
NO170889B (no) 1992-09-14
NL8701507A (nl) 1988-02-01
SE8702705L (sv) 1988-01-03
IL83059A (en) 1992-03-29
IE59613B1 (en) 1994-03-09
NL193136C (nl) 1998-12-04
FI872903A0 (fi) 1987-07-01
KR950005302B1 (ko) 1995-05-23
AU7504087A (en) 1988-01-07
FR2601014A1 (fr) 1988-01-08
HU200777B (en) 1990-08-28
DK161080B (da) 1991-05-27
NL193136B (nl) 1998-08-03
US4933443A (en) 1990-06-12
AR243893A1 (es) 1993-09-30
US4812561A (en) 1989-03-14
CN87105009A (zh) 1988-03-23
AU594167B2 (en) 1990-03-01
DK336487A (da) 1988-01-03
DK161080C (da) 1991-11-11
GB8715064D0 (en) 1987-08-05
AT392472B (de) 1991-04-10
HK47893A (en) 1993-05-27
NZ220764A (en) 1989-09-27
NO872729D0 (no) 1987-06-30
FI89052C (fi) 1993-08-10
BE1001691A4 (fr) 1990-02-13
ATA165887A (de) 1990-09-15
DK336487D0 (da) 1987-06-30
GB2192183B (en) 1990-05-16
DE3721913A1 (de) 1988-01-07
FI89052B (fi) 1993-04-30
PL159180B1 (pl) 1992-11-30
CN1015106B (zh) 1991-12-18
SE466257B (sv) 1992-01-20
HUT44257A (en) 1988-02-29
FI872903L (fi) 1988-01-03
FR2601014B1 (fr) 1990-09-14
CA1283405C (en) 1991-04-23

Similar Documents

Publication Publication Date Title
ES2008759A6 (es) Procedimiento para la fabricacion de un hidrato del acido 7b -(z)-2-(2-aminotiazol-4-il)-4-carboxibut-2-enoilamino -3- cefem-4-carboxilico.
IT8022545A0 (it) Struttura e composizione getteranti, particolarmente adatti per basse temperature.
DE3382000D1 (de) 2,4-dihalo-5-substituierte phenylhydrazine und deren herstellung und verwendung.
ES493474A0 (es) Procedimiento para producir el compuesto (n-fosfonacetil-l- aspartato) (1,2-diaminociclohexano) platino (ii).
FI844383L (fi) Foerfarande foer framstaellning av nya 7-karboximetoxi-furo-(3,4-c)-pyridinderivat.
IT7926833A0 (it) Procedimento per la fabbricazione "in loco" di elettrodi di carbone.
SE426833B (sv) Forfarande for framstellning av nya gona-4,9(10)-diener
AR205686A1 (es) Procedimiento para la produccion de compuestos de n-(4-aminofenil)-n' n'-dimetilacetamidinas de propiedades parasiticidas particularmente antihelminticas
ES493650A0 (es) Procedimiento para la fabricacion de 2(3,4,5-trimetoxifenil)tiazoles,4,5-disubstituidos
ES515457A0 (es) "procedimiento para la fabricacion de cuerpos moldeables aislantes del calor, para la construccion".
IT1145435B (it) Procedimento per la produzione di 2,3-dimetilbutene-2
NO157099C (no) FremgangsmŸte for fremstilling av 1,8-dihydroksy-10-acyl-9-antron-derivater.
JPS52108770A (en) Manufacture for direct heat type cathode
ES291665Y (es) Recombinador para la oxidacion del hidrogeno contenido en el aire.
AR218631A1 (es) Procedimiento para la produccion de acidos 5-sustituidos-1,2-dihidro-3h-pirrolo(1,2,a-)-pirrol-1-carboxilicos
IT8220803A0 (it) Procedimento per la preparazione del 2,3-diidro-2,2-dimetilbenzofuran-7olo.
ES515446A0 (es) Procedimiento para la obtencion de derivados del acido 1,2,5-oxadiazol-3,4-dicarboxilico.
IT1023214B (it) Indrossiindani i,i,3 sostituiti e procedimento per la loro producione
IT1145279B (it) Procedimento per la produzione di 3-(4)-formiltriciclo(5,2,1,0,2,6)-decene-8
ES520201A0 (es) Procedimiento para la obtencion de derivados de 1,4-dihidropiridina.
IT8024353A0 (it) Procedimento per la preparazione di 2,5-dimetil 2,4-esadiene.
JPS5360761A (en) Open show case
SU836133A1 (ru) Устройство дл охлаждени проката
AR212235A1 (es) Procedimiento para la preparacion de imidas del acido 5-endo-(3-indolecarboniloxi)-n-(aminoquilo inferior)-biciclo(3.3.1)-heptano-2,3-di-endo-carboxilico
ES507200A0 (es) Procedimiento para la fabricacion de derivados de la 5,6,7.8-tetrahidro-1,6-naftiridina.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070703